Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. All News
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about BEIGENE, LTD.
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
PU
10/13BEIGENE, LTD. : Termination of a Material Definitive Agreement, Other Events, Financial St..
AQ
10/12BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target
MT
10/11BEIGENE : Brukinsa Approved in Australia for Mantle Cell Lymphoma
MT
10/10BeiGene Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mant..
CI
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/08BEIGENE : Drug for Waldenstrom's Macroglobulinemia Wins Regulatory Nod in Australia
MT
10/07BEIGENE : Brukinsa Approved in Australia for Waldenstrom's Macroglobulinemia
MT
10/07BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
BU
10/07Beigene, Ltd. Announces First Regulatory Approval in Australia for Brukinsa for Treatme..
CI
09/24LEAP THERAPEUTICS : Raises $104 Million After Completing Securities Offering; Stock Rises
MT
09/23INSIDER SELL : Beigene
MT
09/21BEIGENE : Added to FTSE Russell Indices
MT
09/20BEIGENE : European commercial team is preparing to launch BRUKINSA, the company's first me..
PU
09/20BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/20BeiGene Receives Positive CHMP Opinion for BRUKINSA« (Zanubrutinib) for the Treatment o..
CI
09/20BEIGENE : Wins Positive Opinion from Europe's Drug Regulator for Waldenstrom's Macroglobul..
MT
09/20BEIGENE : Announces Inclusion in FTSE Russell Indices
BU
09/20BEIGENE, LTD.(SEHK : 6160) added to FTSE All-World Index
CI
09/17Asian ADRs Move Lower in Friday Trading
MT
09/17US Futures Modestly Lower Ahead of Fed Meeting Next Week
MT
09/17BEIGENE : Receives Positive Opinion for Brukinsa by European Medicines Agency; Shares Clim..
MT
09/17Top Premarket Gainers
MT
09/17BEIGENE : Receives Positive CHMP Opinion for BRUKINSA« (Zanubrutinib) for the Treatment of..
BU
09/17BeiGene Receives Positive CHMP Opinion for BRUKINSA« (Zanubrutinib) for the Treatment o..
CI
09/17BeiGene Gets CHMP Backing of Brukinsa in Waldenstrom's Macroglobulinemia
DJ
09/16Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon
MT
09/16Health Care Stocks Falling Thursday Afternoon
MT
09/16INSIDER SELL : Beigene
MT
09/16LEAP THERAPEUTICS : Says Additional Data from Mid-Stage Study Show Potential of Cancer Com..
MT
09/16BEIGENE : US FDA Grants BeiGene Accelerated Approval for Marginal Zone Lymphoma Treatment
MT
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/15BEIGENE : With its second internally developed medicine filed outside China, BeiGene furth..
PU
09/15BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/15Health Care Stocks Edge Higher Premarket Wednesday
MT
09/15BEIGENE : Says US FDA Grants it Accelerated Approval for Brukinsa for Relapsed or Refracto..
MT
09/15BEIGENE : U.S. FDA Grants BRUKINSA« (Zanubrutinib) Accelerated Approval in Relapsed or Ref..
BU
09/15BeiGene, Ltd. announces U.S. Food and Drug Administration Grants Brukinsa Approval in R..
CI
09/14INSIDER BUY : Beigene
MT
09/13Leap Therapeutics Sees Positive Data for Trial of Cancer Treatment
DJ
09/13BEIGENE : US FDA Accepts BeiGene's Biologics License Application for Cancer Drug; Shares J..
MT
09/13BEIGENE : Says US FDA Accepts Biologics License Application for Cancer Drug Tislelizumab
MT
09/13BEIGENE : Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab ..
BU
09/13BeiGene, Ltd. Announces U.S. FDA Acceptance of Biologics License Application for Tislel..
CI
09/12BEIGENE : to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
BU
09/12BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 202..
CI
09/03BEIGENE : Grants Share Options to Four Employees
MT
09/02BEIGENE : This marks the second FDA approval for BRUKINSA and its third approval in Walden..
PU
09/02BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/02HANG SENG : Hong Kong Stocks Finish Slightly Higher; BeiGene Rises 5%
MT
09/02BEIGENE : US FDA Approves BeiGene's Cancer Medicine as Treatment for Rare Lymphoma; Shares..
MT
09/01BEIGENE : Brukinsa Gets FDA Nod for Treatment of Waldenstrom's Macroglobulinemia
MT
09/01BEIGENE : U.S. FDA Grants BRUKINSA« (Zanubrutinib) Approval in Waldenström's Macroglobulin..
BU
09/01BeiGene, Ltd. Receives Approval from the U.S. Food and Drug Administration of BRUKINSA«..
CI
08/30Asian ADRs Move Lower in Monday Trading
MT
08/30BEIGENE : H1 Loss Narrows, Revenue Climbs on Increased Income From Products, Collaboration..
MT
08/26BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/26HUTCHMED CHINA : BeiGene Start US Clinical Trial of Combination Therapy for Breast Cancer
MT
08/26HUTCHMED CHINA : Doses First Patient in Study of Potential Drug for Breast, Endometrial Ca..
MT
08/26HUTCHMED CHINA : Launches Early-Stage Study of Cancer Combo Therapy in US
MT
08/24BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo..
PU
08/24BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/23BEIGENE : Says Chinese Regulator Accepts Supplemental Biologics License Application for Ca..
MT
08/23BeiGene Announces Acceptance of a Supplemental Biologics License Application in China f..
CI
08/22BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo..
BU
08/19BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA« (Dinutuximab Beta) for ..
PU
08/19BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/18BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for P..
AQ
08/18BEIGENE : Swiss Regulator Begins Review of BeiGene's Marketing Application for Lymphoma Dr..
MT
08/18BEIGENE : Announces Acceptance by Swissmedic of Marketing Authorization Application for BR..
BU
08/18BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for B..
CI
08/17BEIGENE : UK Partner's Cancer Drug Gets Conditional Approval in China
MT
08/17BEIGENE : EUSA Pharma Win China Regulatory Ok of Qarziba for High-Risk Neuroblastoma
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BEIGENE, LTD.
11/11/21